Table 2.
Details of secondary, tertiary and any further treatment following initial laser or anti-VEGF antibody treatment, based on 168 children for whom one-year follow-up data were available (reporting unit: right eye)
| Secondary treatment | ||||
|---|---|---|---|---|
| Argon laser | Anti-VEGF antibody | Missing data | Total | |
| Initial treatment | ||||
| Argon laser | 5 | 7 | 2 | 14 |
| VEGF inhibitor | 0 | 2 | 1 | 3 |
| Total | 5 | 9 | 3 | 17 |
| Tertiary treatment | ||||
|---|---|---|---|---|
| Argon laser | Anti-VEGF antibody/plus laser | Surgery | Total | |
| Initial treatment | ||||
| Argon laser | 3 | 0 | 2 | 5 |
| VEGF inhibitor | 0 | 1 | 0 | 1 |
| Total | 3 | 1 | 2 | 6 |
| Any further treatment at 1 year | ||||
|---|---|---|---|---|
| Argon laser | Anti-VEGF antibody/plus laser | Surgery | Total | |
| Initial treatment | ||||
| Argon laser | 3 | 1 | 1 | 5 |
| VEGF inhibitor | 0 | 2 | 0 | 2 |
| Total | 3 | 3 | 1 | 7 |